FY2025 EPS Estimates for Immatics Cut by Cantor Fitzgerald

Key Points

• Analysts at Cantor Fitzgerald have reduced their FY2025 earnings per share estimate for Immatics to ($2.15), down from a previous estimate of ($1.40).
• Immatics reported a loss of ($0.66) EPS for the last quarter, failing to meet the consensus estimate of ($0.38).
• Institutional investors now hold 64.41% of Immatics' stock, with significant increases in holdings from firms like T. Rowe Price Investment Management.

Immatics N.V. (NASDAQ:IMTX - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for Immatics in a research note issued to investors on Thursday, August 14th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will earn ($2.15) per share for the year, down from their previous forecast of ($1.40). The consensus estimate for Immatics' current full-year earnings is ($0.72) per share. Cantor Fitzgerald also issued estimates for Immatics' FY2026 earnings at ($1.55) EPS.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.28). The company had revenue of $6.48 million during the quarter, compared to analyst estimates of $13.05 million. Immatics had a negative return on equity of 15.60% and a negative net margin of 59.29%.

IMTX has been the topic of a number of other reports. Zacks Research lowered Immatics from a "hold" rating to a "strong sell" rating in a research note on Friday, August 15th. Deutsche Bank Aktiengesellschaft started coverage on Immatics in a research note on Wednesday, May 28th. They issued a "buy" rating and a $10.00 price objective on the stock. Finally, Wall Street Zen cut Immatics from a "hold" rating to a "strong sell" rating in a research note on Thursday, May 22nd. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Immatics presently has an average rating of "Moderate Buy" and a consensus target price of $14.67.

Immatics Price Performance

Shares of Immatics stock traded up $0.06 during midday trading on Monday, reaching $5.69. The company had a trading volume of 302,231 shares, compared to its average volume of 583,837. The stock has a fifty day moving average price of $6.00 and a 200 day moving average price of $5.21. The firm has a market cap of $691.62 million, a PE ratio of -8.75 and a beta of 0.93. Immatics has a fifty-two week low of $3.30 and a fifty-two week high of $13.09.

Institutional Investors Weigh In On Immatics

Several large investors have recently added to or reduced their stakes in the business. Guggenheim Capital LLC acquired a new position in Immatics during the 4th quarter worth approximately $101,000. Marshall Wace LLP acquired a new position in Immatics during the 4th quarter worth approximately $409,000. T. Rowe Price Investment Management Inc. raised its stake in Immatics by 43.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,604,777 shares of the company's stock worth $75,400,000 after buying an additional 3,225,141 shares during the period. Virtus ETF Advisers LLC raised its stake in Immatics by 34.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company's stock worth $68,000 after buying an additional 2,479 shares during the period. Finally, Northern Trust Corp raised its stake in Immatics by 31.5% during the 4th quarter. Northern Trust Corp now owns 47,226 shares of the company's stock worth $336,000 after buying an additional 11,304 shares during the period. Institutional investors and hedge funds own 64.41% of the company's stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.